CHRONIC TOXICITY STUDIES OF PARENTERAL FORM OF INHIBITOR FUNCTION ADRENAL GLANDS o, p'-DDD (chloditan)

Authors

DOI:

https://doi.org/10.11603/2312-0967.2023.1.13624

Keywords:

chloditan, parenteral form, histological analysis, chronic toxicity

Abstract

The aim of the work. Experimental study of chronic toxicity of 5 % solution for injection of inhibitor adrenal o,p'-DDD.

Мaterials and Methods. Object of research – parenteral form o,p'-DDD. The experiment was carried out on male Wistar rats for 90 days. At baseline and at 14, 30 and 90 days, the blood and urine tests were performed. At the end of the experiment histological examinations carried out of adrenal, kidney, liver and heart.

Results and Discussion. Hematologic blood tests showed that after 14 days of administration of the drug solution of solvent and observed significant changes in hematological parameters (white blood cells, and platelets). This indicates that manifestations the toxic effect is primarily due to the action of the solvent. Histological examination of the main organs of animals found significant damage to the cells of the adrenal zona fasciculata, and small changes in the liver. Heart and kidney damage have not received.

Conclusions. At 90-day intraperitoneal injection of the drug in the solvent and o,p'-DDD (chloditan) observed toxic effects, primarily due to the action of a solvent. The long-term (90 days) continuous administration of the drug is an activation of the hypothalamic-pituitary-adrenal system in response to the significant reduction of glucocorticoid hormones in the destruction of their producing cells. It was demonstrated that the introduction of the solvent and the solution o,p'- DDD (chloditan) did not affect the urinary system. Histological examination established that the introduction of peritoneal solution o, p'-DDD produces a particular damaging effect on the cells of the adrenal zona fasciculata. The solution in the o,p'-DDD has a moderate effect on the liver of rats. The solvent is also not indifferent by these bodies.

Author Biographies

O. V. Simurov, State Institution «V. P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine»

PhD (Chemistry), Senior Researcher of the Department of Epidemiology of Endocrine Diseases

Y. G. Bal’on

DSc (Chemisrty), Professor, Kyiv, Ukraine

L. I. Poliakova, State Institution «V. P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine»

PhD (Biology), Senior Researcher of the Department of Endocrinology of Reproduction and Adaptation

V. V. Khovaka, State Institution «V. P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine»

PhD (Medecine), Leading Researcher of the Department of Age Endocrinology and Clinical Pharmacology

N. V. Simurova, National University of Food Technology

PhD (Chemistry), Associate Professor of the Food Chemistry Department

V. I. Kravchenko, State Institution «V. P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine»

DSc (Medecine), Head of the Department of Epidemiology of Endocrine Diseases

References

Hatipoglu B. Cushing’s syndrome. J Surg Oncol. 2012;106: 565-71. https://doi.org/10.1002/jso.23197. DOI: https://doi.org/10.1002/jso.23197

Tronko MD, Komisarenko ІV, Balon YaG. Kvachenyuk АМ, Lisenko ОG, Simurov ОV, Samson OYa. [Inhibitors of hormonal production in the epidermis and their congestion in clinical practice]. Zhurn AMN Ukr. 2010;16(2): 271-87. Ukrainian.

Lukashenia OS, Levchuk NI, Kovzun OI. [Study of the mechanisms for cytotoxic effects of adrenocorticolytic and antimitotic drugs inhuman adrenocorticocytes]. Endokrynol. 2019;20;24(4):331-336. https://doi.org/10.31793/1680-1466.2019.24-4.332. Ukrainian. DOI: https://doi.org/10.31793/1680-1466.2019.24-4.332

Kvachenyuk АМ, Suprun IS, Negrienko KV, Kvacheneyuk DA. [Adrenocortical cancer: diagnostic and curative peculiarities]. Endokrynol. 2015;20;20(3): 604-16. Ukrainian.

Webb SM, Ware JE, Forsythe A. Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing’s disease. Eur J Endocrinol. 2014;171(1): 89-98. DOI: 10.1530/EJE-13-1013. DOI: https://doi.org/10.1530/EJE-13-1013

Balon YaG, Reznikov OG, Tronko MD, Simurov OV, Vakulenko LI, Tochilkina LM, inventors; State University "Institute of Endocrinology and Metabolism named after V.P. Komisarenka National Academy of Sciences of Ukraine", patent holder. The method of obtaining an injection solution of 1-(ortho-chlorophenyl)-1-(para-chlorophenyl)-2,2-dichloroethane (chloditan), which is an inhibitor of the function of the adrenal cortex. Patent of Ukraine No. 94543. 2011 May 10. Ukrainian.

Bal’on YaG, Reznikov AG, Tronko MD, Pasteur IP, Simurov AV. [Inhibition of adrenal cortex function with o,p'-DDD (chloditan) in vitro and in vivo]. Reports of the National Academy of Sciences of Ukraine. 2011;11: 150-5. Ukrainian.

Balon YaG, Simurov AV, Gureeva SM. [Investigation of the chemical-pharmaceutical properties of the solution for injection of the adrenal gland inhibitor o,p'-DDD.( Chloditan)]. Endokrynol. 2012;20;17(2): 44-9. Ukrainian.

Balon YaG, Hovaka VV, Simurov OV. [Study of the acute toxicity of the parenteral form of o,p'-DDD (chlodithan)]. Farmakol i med toksykol. 2010;3 (16): 12-6. Ukrainian.

Stefanov OV, editor. Preclinical research of medicines: Method. Recommendations. [Доклінічні дослідження лікарських засобів] Kyiv: Avicenna; 2001. Ukrainian.

Downloads

Published

2023-03-30

How to Cite

Simurov, O. V., Bal’on, Y. G., Poliakova, L. I., Khovaka, V. V., Simurova, N. V., & Kravchenko, V. I. (2023). CHRONIC TOXICITY STUDIES OF PARENTERAL FORM OF INHIBITOR FUNCTION ADRENAL GLANDS o, p’-DDD (chloditan). Pharmaceutical Review Farmacevtičnij časopis, (1), 43–49. https://doi.org/10.11603/2312-0967.2023.1.13624

Issue

No. 1 (2023)

Section

Pharmacological researches of biologically active substances

License

Copyright (c) 2023 Pharmaceutical Review / Farmacevtičnij časopis

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The authors who publish their materials in this journal agree with the following terms:

  • Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal Результат пошуку зображень за запитом "CC-BY logo".
  • Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.

Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).